WOCKHARDT

BSE: 532300 20 Aug 2025

Healthcare

₹ 1493

Wockhardt Ltd specializes in Pharmaceuticals within the Healthcare sector.

WOCKHARDT

BSE: 532300 20 Aug 2025

Healthcare

₹ 1493

Wockhardt Ltd specializes in Pharmaceuticals within the Healthcare sector.

Book Value

170.0

Dividend Yield

0.0%

Debt to Equity

0.65

Stock P/E

475.0

Market Cap

24,245 Cr

WOCKHARDT - Share Price & Details

Market Cap

₹24,245

High /Low

1,870 / 915.0

Stock P/E

475.0

Book Value

₹170.0

Dividend Yield

0.0

ROCE

4.4

ROE

₹-0.53

Face Value

5.0

PEG Ratio

19.7

EVEBITDA

₹64.2

Debt

1,796

CMP / FCF

-211.0

Debt to equity

₹0.65

NP Ann

-12.0

High price all time

1,999

Piotroski score

₹5.0

Graham Number

107.0

No. Eq. Shares

16.2

Net CF

₹-428

Net profit

51.0

Price to book value

8.78

Interest Coverage

₹1.28

Low price all time

61.3

Industry PE

33.5

Reserves

₹2,682

Free Cash Flow

₹-508

Price Chart

Volume Chart

Peer Comparison

Stock	Total Income	Net Profit	Net Sales	EPS	Market Cap (in Cr)	P/E
Shyama Computronics and Servic	1.48	0.93	0.67	0.00	5.33	35.5
Triochem Products Ltd.,	3.25	-4.52	NA	-18.44	0
WOCKHARDT LTD.	4380.0	690.0	4130.0	4.25	24,245	475.0
Eris Lifesciences Limited	6013.2	999.9	5786.4	7.33	23715	61.2
ASTRAZENECA PHARMA INDIA LTD.	5375.5	558.3	5263.1	22.33	21004	99.3

Peer Comparison Chart

About WOCKHARDT

Wockhardt Ltd, with Security Code 532300, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.

Latest News

Can Wockhardt Limited (WOCKPHARMA) Maintain Its Valuation - Explosive earnings growth

(30 Jul 2025)

Can Wockhardt Limited (WOCKPHARMA) Maintain Its Valuation ✌️【Trading Ideas】✌️ We turn market noise into real opportunity — with alerts on...

Quarterly Table

Standalone Consolidated

Metrics	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Sales	291.0	251.0	260.0	288.0	355.0	352.0	370.0	325.0	355.0	413.0
Expenses	321.0	256.0	270.0	263.0	401.0	272.0	321.0	263.0	249.0	282.0
Operating Profit	-30.0	-5.0	-10.0	25.0	-46.0	80.0	49.0	62.0	106.0	131.0
OPM %	-10.31%	-1.99%	-3.85%	8.68%	-12.96%	22.73%	13.24%	19.08%	29.86%	31.72%
Other Income	-156.0	-8.0	6.0	5.0	24.0	27.0	11.0	6.0	14.0	25.0
Interest	58.0	58.0	59.0	61.0	59.0	58.0	53.0	48.0	40.0	41.0
Depreciation	45.0	44.0	44.0	43.0	45.0	43.0	43.0	42.0	40.0	46.0
Profit before tax	-104.0	-101.0	-107.0	-74.0	-126.0	6.0	-36.0	-22.0	40.0	69.0
Tax %	3.5%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Net Profit	-299.0	-115.0	-107.0	-74.0	-126.0	6.0	-36.0	-22.0	40.0	69.0
EPS in Rs	-20.8	-8.01	-7.39	-5.14	-8.71	0.39	-2.34	-1.4	0	4.25

Metrics	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	699.0	678.0	644.0	753.0	701.0	700.0	739.0	809.0	721.0	743.0
Expenses	654.0	675.0	628.0	681.0	664.0	803.0	648.0	699.0	593.0	679.0
Operating Profit	45.0	3.0	16.0	72.0	37.0	-103.0	91.0	110.0	128.0	64.0
OPM %	6.44%	0.44%	2.48%	9.56%	5.28%	-14.71%	12.31%	13.6%	17.75%	8.61%
Other Income	-1.0	-64.0	0.0	24.0	8.0	54.0	30.0	9.0	8.0	15.0
Interest	83.0	76.0	79.0	76.0	77.0	73.0	73.0	73.0	60.0	48.0
Depreciation	66.0	56.0	55.0	55.0	55.0	58.0	54.0	55.0	55.0	53.0
Profit before tax	-102.0	-97.0	-104.0	-35.0	-87.0	-180.0	-6.0	-9.0	21.0	-22.0
Tax %	-2.9%	22.8%	15.3%	108.6%	-1.1%	-1.7%	-166.7%	-77.8%	4.8%	0%
Net Profit	-102.0	-237.0	-136.0	-73.0	-86.0	-177.0	-16.0	-16.0	20.0	-45.0
EPS in Rs	-6.62	-14.37	-9.28	-5.37	-5.75	-11.64	-0.95	-1.47	0.91	0

Shareholding Distribution

Shareholding Pattern

Compounded Data

Consolidated

Standalone

Compounded Sales Growth
10 Years:	-4%
5 Years:	-6%
3 Years:	5%
TTM:	29%

Compounded Profit Growth
10 Years:	0%
5 Years:	0%
3 Years:	0%
TTM:	56%

Stock Price CAGR
10 Years:	0%
5 Years:	45%
3 Years:	68%
1 Year:	138%

Compounded Sales Growth
10 Years:	-5%
5 Years:	-5%
3 Years:	1%
TTM:	7%

Compounded Profit Growth
10 Years:	0%
5 Years:	0%
3 Years:	0%
TTM:	66%

Stock Price CAGR
10 Years:	0%
5 Years:	45%
3 Years:	68%
1 Year:	138%

All Deals

Date	Stock	Party	Deal	Acq. Mode	Trans.	Quan.	Price	Value

WOCKHARDT

WOCKHARDT

WOCKHARDT - Share Price & Details

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

About WOCKHARDT

Latest News

Wockhardt Eyes ‘Healthy Bottom Line’ In Coming Quarters Amid US Tariff Concerns

Wockhardt reports Q1 FY26 loss at Rs. 108 Cr

Wockhardt Q1 Results: Net loss widens to ₹90 crore, revenue flat

Pharmaceuticals Firm Wockhardt Reports Widening Of Loss After Tax At ₹108 Crore

Here's Why Wockhardt Limited's (NSE:WOCKPHARMA) CEO May Deserve A Raise

Can Wockhardt Limited (WOCKPHARMA) Maintain Its Valuation - Explosive earnings growth

Is Wockhardt Limited (WOCKPHARMA) a Good Long Term Bet - Superior stock growth

Wockhardt Limited (532300) Hits 52 Week High - Skyrocketing profit margins

Wockhardt Shares Gain 3.5% on Exit from Loss-Making US Generics Business

Stocks To Watch Today: Wockhardt, RVNL, SBI, Tata Motors, HUL, Religare Enterprises, VIP Industries

Wockhardt shares in focus after announcing an exit from loss-making US generics business

Wockhardt Ltd dumps US generic pharma segment after losses, bets on antibiotics and insulin

Wockhardt Exits US Generics Pharma Business To Focus On Innovation-Driven Areas; Details Here

Wockhardt to exit US generic pharma segment, shut down 2 subsidiaries

Wockhardt to exit US generic pharma segment to unlock capital for high-impact areas

Wockhardt exits its US generics business

Wockhardt exits US generics business, files for liquidation of subsidiaries

Wockhardt activates Zaynich push, eyes global licensing deals

Infibeam Avenues Ltd leads losers in 'A' group

Buy, Sell Or Hold: Wockhardt, Oswal Pumps, JSW Infra, IRFC, Zee, PNB — Ask Profit

Wockhardt Ltd Achieves 52-Week High Amid Declining Investor Participation

Wockhardt Experiences Revision in Its Stock Evaluation Amid Mixed Small-Cap Performance

Wockhardt shares jump 17%, hit fresh 52-week high

Rekha Jhunjhunwala Portfolio: Multibagger Pharma Stock Zooms 17%; 207% Up In 1 Year

Wockhardt Limited's (NSE:WOCKPHARMA) 26% Price Boost Is Out Of Tune With Revenues

Wockhardt Stock Skyrockets In A Day: What’s Fueling The Rally?

Rekha Jhunjhunwala portfolio stock soars 17%; zooms over 950% in 2 years

Wockhardt Share Price Today Up 13%

Wockhardt looking at FY27 US launch for 'miracle' antibiotic Zaynich

Wockhardt Q4 Results: Net Loss Narrows As Ebitda Turns Positive

Wockhardt Q4 earnings: Net loss narrows to Rs 45 crore; revenue, EBITDA and more

Buy, Sell Or Hold: Mazagon, Cochin Shipyard, Infosys, Wockhardt, ONGC, Piramal Pharma — Ask Profit

Wockhardt sells USFDA-approved migraine tablet to Senores Pharma

Wockhardt Faces Short-Term Challenges Amidst Broader Market Resilience and Long-Term Growth

Private companies among Wockhardt Limited's (NSE:WOCKPHARMA) largest stockholders and were hit after last week's 9.8% price drop

Senores Pharma shares in focus after deal to acquire USFDA-approved epilepsy drug from Wockhardt

Wockhardt Faces Continued Decline Amid Broader Market Volatility and Sector Underperformance

Wockhardt Faces Significant Decline Amid Broader Market Challenges and High Volatility

US tariffs, if extended to Indian pharma industry, will be a challenge: Wockhardt's Huzaifa Khorakiwala

Wockhardt incorporates new step-down subsidiary in Ireland

Wockhardt & 4 other pharma stocks to benefit as CDMO market is expected to grow to $300 billion by 2028

How Wockhardt is packing for the road less travelled | Company Business News

Wockhardt looks to exit US generics biz; tariff burden may hit consumers

JSW Holdings, Wockhardt and Shakti Pumps locked in 5% upper circuit on March 19

Rakesh Jhunjhunwala’s portfolio gains 19,19,23,388.25 in just 1 day: Multibagger pharma stock locked in upper circuit on March 19

Wockhardt swings to profit in Q3, reports multifold growth in EBITDA

DIIs place big bets on 2 pharma giants. Multibaggers in the making?

Wockhardt stock up 10% as Zaynich achieves 96.8% efficacy in Phase III

Wockhardt Q3 Results: Pharma Major Swings Back To Profit As Expenses Fall

Wockhardt Q3 Results: Net profit comes in ₹20 crore, revenue at ₹721 crore; shares down 3%

Wockhardt Shares Hit 10% Upper Circuit as Zaynich Achieves 96.8% Efficacy

Wockhardt’s ‘miracle drug’ Zaynich: Can it revive the antibiotics market and the company’s fortunes?

Buy, Sell Or Hold: Man Industries, Anant Raj, KPI Green, Sula Vineyards — Ask Profit

Wockhardt Ltd Reports 4.47% Decline on January 13, 2025 Amid Sector Downturn

Wockhardt’s Zaynich antibiotic achieves 97% efficacy against carbapenem-resistant bacteria

Wockhardt Sees New Drugs to Fight Superbugs as Next Growth Driver

Wockhardt gains 4% as drug shows 97% efficacy for drug-resistant bacteria

Wockhardt gains up to 4% after antibiotic Zaynich shows 97% effectiveness in treating drug-resistant infection

Rakesh Jhunjhunwala’s Multibagger Pharma Stock Reports Clinical Breakthrough in Combating Serious Illness

Wockhardt Shares Soar 4% as Zaynich Shows 97% Clinical Efficacy

Wockhardt Experiences Revision in Its Score Amid Strong Market Performance and New Highs

This multibagger pharma stock jumped 9% today; stock up 10x in 21 months

Wockhardt - 8 smallcap stocks surge over 250% since last Christmas

Wockhardt - CY24 sees 91 QIPs, 7 deliver over 100% returns on issue prices

Wockhardt Stock Declines 3.26%, Underperforming Broader Pharmaceuticals Sector

Wockhardt - 15 mutual funds bet big on these 9 stocks in November; 4 of them surge over 100% in CY24

What Wockhardt Limited's (NSE:WOCKPHARMA) 31% Share Price Gain Is Not Telling You

Wockhardt and Cochin Shipyard among 20 smallcap stocks in which 7 mutual funds increased stakes in November

Wockhardt shares add to their 220% gain for 2024 with another 10% surge — Explained

UltraTech Cement, Wockhardt among 108 stocks to hit 52-week high, details here

Why this pharma stock hit nearly 9-year high; froze at 10% upper circuit?